Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 228

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 228
---
                        |     |              |  3,268 |   |     |              |  1,186 |   |
| CASH AND CASH EQUIVALENTS AT THE END OF PERIOD                              |     |            $ |  3,715 |   |     |            $ |    825 |   |

*) less than 1 thousand

<div align='center'>The accompanying notes are an integral part of
these financial statements.

F-38</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

| NOTE 1:- | GENERAL |

On December
17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the “Reincorporation. As a result
of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a
Nevada corporation under the name “Revium Rx.”

In November
2023, the Successor entered into a stock exchange agreement (“Share Exchange”) with Lipovation Ltd, a private Israeli company
engaged in the development of novel pharmaceutical solutions (“Lipovation” or the “Predecessor”). Following the
closing of such agreement on July 23, 2024, the Predecessor became a wholly owned subsidiary of the Company, and as determined by the
Company’s board of directors. Following the closing of the Share Exchange agreement, the Company’s Board of Directors determined
to discontinue all of the Company’s prior activities and efforts in the development and activation of the clinical decision-making
support system which constituted the business of the Successor prior to the closing of the stock exchange agreement, and to focus on
the development of the acquired LipoVation’s business.

Through
its subsidiary LipoVation Ltd, the Company is developing next-generation, lipid-based therapies to address some of the most pressing
challenges in medicine. the Subsidiary is focusing on creating smarter, more targeted treatments that improve how medicines work in the
body, with the goal of increasing effectiveness while reducing side effects. The subsidiary’s pipeline, which is comprised of drug
candidates in various stages of development, includes advanced delivery systems for a variety of indications, including a liposomal antibiotic
targeted at fighting drug-resistant infections and a liposomal therapy designed to boost the impact of cancer treatments.

| b. | Liquidity